Claims for Patent: 8,137,689

Summary for Patent: 8,137,689

Title:	Transplant/implant device and method for its production
Abstract:	A transplant/implant device for delivering at least one predetermined biologically active compound to a human or animal host system or for another biological function in the host system is produced by genetically engineering vital chondrocytes or mixing chondrocytes with another type of native or genetically engineered cells or mixing chondrocytes with artificial particles having a size comparable to the size of cells or combining at least two of the named steps of engineering or mixing and by subjecting the chondrocytes or the mixture comprising the chondrocytes to three dimensional culture conditions for in vitro production of cartilaginous tissue whereby the cells and/or the artificial particles are immobilized in the cartilaginous tissue. The chondrocytes produce and maintain the cartilaginous tissue and the chondrocytes themselves or cells of another cell type immobilized in the cartilaginous tissue are able to produce and secrete the at least one predetermined compound.
Inventor(s):	Grogan; Shawn P. (Rooty Hill, AU), Mainil-Varlet; Pierre (Bern, CH), Muller; Werner (Wiesendangen, CH), Schaffner; Thomas (Munchenbuchsee, CH)
Assignee:	Zimmer GmbH (Winterthur, CH)
Application Number:	10/129,915
Patent Claims:	1. An implant for in vivo production of at least one predetermined biologically active compound, said implant comprising chondrocytes producing and maintaining an extracellular matrix and artificial particles producing the at least one predetermined compound, wherein at least some of the artificial particles are disposed within the extracellular matrix and other than the artificial particles, the implant is generated in vitro without the use of a three dimensional artificial matrix. 2. The implant according to claim 1, wherein the chondrocytes comprise autologous chondrocytes originating from a human or animal into which the implant is to be implanted. 3. The implant according to claim 1, wherein the chondrocytes are heterologous or homologous chondrocytes. 4. The implant according to claim 1, further comprising genetically engineered cells. 5. The implant according to claim 4, wherein the genetically engineered cells are chondrocytes. 6. The implant according to claim 1, wherein the compound is selected from the group consisting of inhibitors of inflammation, hormones, growth factors, coagulation factors, neurotransmitters, neurotrophic factors, and activators or inhibitors of angiogenesis. 7. The implant according to claim 1, wherein the particles are of a size comparable to the size of the cells. 8. The implant of claim 1, wherein the extracellular matrix comprises type II collagen and proteoglycans. 9. The implant of claim 1, wherein the chondrocytes originate from cartilaginous tissue. 10. The implant of claim 1, wherein the chondrocytes are prepared by in vitro differentiation of stem cells or pre-chondrocytes. 11. The implant of claim 1, wherein at least some of the artificial particles disposed within the extracellular matrix are immobilized within the extracellular matrix. 12. The implant of claim 6, wherein the compound is a hormone selected from the group consisting of insulin, parathyroid hormone, and somatotropin. 13. The implant of claim 12, wherein the hormone is insulin. 14. The implant of claim 6, wherein the compound is a growth factor. 15. The implant of claim 14, wherein the growth factor is a bone morphogenic protein.

Details for Patent 8,137,689

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2019-11-11